AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19637474
Drug: Extraction of
RxNorm normalized name: tree of heaven pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extraction of two maxillary first premolars and two mandibular first molars with additional micro-implants for orthodontic anchorage
Trial: 16843643
Drug: Fexofenadine and
RxNorm normalized name: Fexofenadine and pseudoephedrine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine and emollient treatment (Group 1) for 1 week
Trial: 16843643
Drug: Fexofenadine and
RxNorm normalized name: Fexofenadine and pseudoephedrine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine and steroid treatment (Group 2) for 1 week
Trial: 29481430
Drug: Midazolam and
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam and oxycodone
Trial: 27077832
Drug: 5% albumin
RxNorm normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% albumin solution between 8 and 12 hours post burn (n = 23)
Trial: 27077832
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received 5% albumin solution 24 hours post burn (n = 23)
Trial: 22522549
Drug: BQ-123 (ETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQ-123 (ETA receptor antagonist) at 400 nmol/minute for 60 minutes
Trial: 22522549
Drug: BQ-123 (ETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQ-123 (ETA receptor antagonist)
Trial: 17827142
Drug: 3 day
RxNorm normalized name: Kathro 3 Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 day antibiotic therapy
Trial: 17827142
Drug: 8 day
RxNorm normalized name: Jasmiel 28 Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 day antibiotic therapy
Trial: 11172215
Drug: Sucralfate administered
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucralfate administered every 6 hours for 15 days (group A)
Trial: 11172215
Drug: Water for
RxNorm normalized name: WATER FOR INJECTION
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water for injection with strawberry flavor as placebo (group B)
Trial: 3173616
Drug: CA.RP (keto-analogs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA.RP (keto-analogs with low protein diet 0.4 g/kg/day)
Trial: 3173616
Drug: CA.RN (keto-analogs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA.RN (keto-analogs with normal protein diet 1 g/kg/day)
Trial: 25471002
Drug: Antiviral agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral agents
Trial: 25471002
Drug: TENS and
RxNorm normalized name: ECAMSULE 39.6 mg in 1 mL / OCTINOXATE 67.4 mg in 1 mL / TITANIUM DIOXIDE 32.8 mg in 1 mL TOPICAL CREAM [KIEHLS ULTRA LIGHT DAILY UV DEFENSE TONE UP SPF 50 ANTI POLLUTION INSTANTLY BRIGHTENS AND HYDRATES]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TENS and Antiviral agents
Trial: 12612223
Drug: Intratracheal r‐h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratracheal r‐h CuZnSOD (5 mg/kg in 2 mL/kg saline) every 48 hours for up to 1 month
Trial: 12612223
Drug: Intratracheal r‐h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratracheal r‐h CuZnSOD (5 mg/kg in 2 mL/kg saline)
Trial: 10805052
Drug: Candesartan cilexetil/hydrochlorothiazide
RxNorm normalized name: Candesartan Cilexetil/Hydrochlorothiazide 32 MG-25 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan cilexetil/hydrochlorothiazide 8/12.5 mg once daily
Trial: 10805052
Drug: Lisinopril/hydrochlorothiazide 10/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril/hydrochlorothiazide 10/12.5 mg once daily
Trial: 6441624
Drug: Estrogen and
RxNorm normalized name: Conjugated estrogen and norgestrel only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen and calcium treatment
Trial: 31754080
Drug: Mixed flavonoid
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed flavonoid supplementation (678 mg total, including 200 mg quercetin, 368 mg green tea catechins, 128 mg anthocyanins)
Trial: 29098555
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with cisplatin, etoposide, and irinotecan
Trial: 22697628
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (implants surrounded by bone, no GBR)
Trial: 12660500
Drug: Rapamycin 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapamycin 2 mg/day
Trial: 10589950
Drug: Sirolimus (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (1 or 3 mg/m2/day) with full‐dose CsA
Trial: 10589950
Drug: Sirolimus (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (1, 3, or 5 mg/m2/day) with reduced‐dose CsA
Trial: 10589950
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo with full‐dose CsA)
Trial: 10589950
Drug: Sirolimus (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (3 mg/m2/day) with full‐dose CsA
Trial: 10589950
Drug: Sirolimus with
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus with CsA and steroids
Trial: 8929747
Drug: Diltiazem 30
RxNorm normalized name: diltiazem 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 30 mg 3 times daily
Trial: 8929747
Drug: Warfarin 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin 25 mg oral dose
Trial: 6355792
Drug: Cimetidine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1.0 g/day)
Trial: 6732224
Drug: Topical 10%
RxNorm normalized name: urea topical 10% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 10% acyclovir in polyethylene glycol ointment
Trial: 21235040
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (up to 10 sessions, average of 8.6 sessions per patient)
Trial: 12588269
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus planned Gp IIb/IIIa inhibition (n = 3011)
Trial: 12588269
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus planned Gp IIb/IIIa inhibition
Trial: 9546934
Drug: Heparin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin administration via nomogram (Group I)
Trial: 9546934
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing scheme (Group II)
Trial: 9546934
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing scheme (Group III)
Trial: 1866869
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg p.o.
Trial: 1866869
Drug: Gentamicin 1.5
RxNorm normalized name: HYDROCORTISONE ACEPONATE 1.11 mg in 1 mL / MICONAZOLE NITRATE 17.4 mg in 1 mL / GENTAMICIN 1.5 mg in 1 mL AURICULAR (OTIC) SUSPENSION [EASOTIC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 1.5 mg/kg IV
Trial: 6337697
Drug: DES 1
RxNorm normalized name: SENNOSIDES 15MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DES 1 mg orally three times daily or orchiectomy
Trial: 6337697
Drug: DES plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DES plus cyclophosphamide at 1 mg/m2 iv every three weeks
Trial: 6337697
Drug: Estracyt plus
RxNorm normalized name: Estracyt
DrugBank: Estramustine phosphate (DB14674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estracyt plus cyclophosphamide at 1 g/m2 iv every three weeks
Trial: 6337697
Drug: Chemotherapy (DES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (DES plus cyclophosphamide or Estracyt plus cyclophosphamide)
Trial: 12969694
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy alone
Trial: 29045520
Drug: Cabozantinib (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (140 mg/day) in RET M918T-positive tumors
Trial: 29045520
Drug: Cabozantinib (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (140 mg/day) in RET M918T-negative tumors
Trial: 25271811
Drug: Fixed-dose losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose losartan 50 mg/hydrochlorothiazide 12.5 mg/amlodipine 5 mg (L50/H12.5/A5)
Trial: 25271811
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg/hydrochlorothiazide 12.5 mg (L50/H12.5)
Trial: 24298783
Drug: Abdominal acupuncture
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal acupuncture with basic treatment (psychological counseling and Chinese patent medicine Rupixiao)
Trial: 24298783
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment with basic treatment only
Trial: 22292367
Drug: Kudiezi injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kudiezi injection plus traditional Chinese medicine (TCM) synthesis rehabilitation project
Trial: 19332202
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention (PCI) and stenting with optimal medical therapy (1,101 patients)
Trial: 19332202
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy alone (1,100 patients)
Trial: 19332202
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy in non-LAD group
Trial: 9470078
Drug: Volume group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume group received a rapid (10‐min) 6 ml/kg infusion of a 6% hydroxyethyl starch preparation during mechanical ventilation (MV).
Trial: 7887106
Drug: HF+TEA group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HF+TEA group (high-dose fentanyl + TEA with 10 ml bupivacaine 5 mg.ml‐1 followed by 4 ml every hour)
Trial: 7887106
Drug: LF+TEA group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LF+TEA group (low-dose fentanyl + TEA)
Trial: 7887106
Drug: HF group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HF group (high-dose fentanyl 55 micrograms.kg‐1)
Trial: 2974978
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg dose of synthetic human calcitonin administered 6-hourly by intravenous route
Trial: 2974978
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg dose of synthetic human calcitonin administered 6-hourly by intravenous route
Trial: 2974978
Drug: Incremental doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incremental doses of calcitonin after 3 injections if blood calcium level had not been reduced by more than 0.4 mmoles/l
Trial: 25599346
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with voriconazole and anidulafungin
Trial: 30049743
Drug: Voriconazole monotherapy
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole monotherapy
Trial: 25599346
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with voriconazole and anidulafungin (post hoc analysis)
Trial: 25599346
Drug: Voriconazole monotherapy
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole monotherapy (post hoc analysis)
Trial: 22107691
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (vitamin D and phosphate binders)
Trial: 12542601
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg lansoprazole (u.i.d) for 14 days
Trial: 12542601
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg rebamipide (t.i.d) for 14 days
Trial: 12542601
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg famotidine (b.i.d) for 14 days
Trial: 12542601
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg roxatidine (b.i.d) for 14 days
Trial: 10632645
Drug: BTC regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTC regimen (colloidal bismuth subcitrate 220 mg b.d., tinidazole 500 mg b.d., clarithromycin 250 mg b.d.)
Trial: 10632645
Drug: OBTC regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBTC regimen (omeprazole 20 mg daily for 4 weeks with BTC regimen during the first week)
Trial: 9505989
Drug: Olanzapine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5 mg) and Imipramine (75 mg) (combined)
Trial: 3090978
Drug: Elemental diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elemental diet administered by needle‐catheter jejunostomy (NCJ)
Trial: 18657739
Drug: Intra-articular sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular sufentanil (5 microg) with ropivacaine (100 mg) and clonidine (1 microg/kg)
Trial: 18657739
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with ropivacaine (100 mg) and clonidine (1 microg/kg) without sufentanil
Trial: 16308129
Drug: Regular follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular follow-up by the nutrition team (weekly in hospital, monthly after discharge)
Trial: 12549816
Drug: Monthly mail-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly mail-based educational intervention to patients and prescribers regarding medication adherence (intervention group)
Trial: 12549816
Drug: Monthly mail-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly mail-based educational intervention
Trial: 10367596
Drug: L-DOPA (0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-DOPA (0.10 g, p.o., t.i.d., for 1 day)
Trial: 10367596
Drug: L-DOPA (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-DOPA (0.25 g, p.o., t.i.d., for 2 days)
Trial: 10367596
Drug: L-DOPA (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-DOPA (both doses)
Trial: 3430499
Drug: Cefonicid (1-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefonicid (1-g intravenous dose after cord clamping)
Trial: 3430499
Drug: Cefoxitin (2-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (2-g intravenous dose after cord clamping and at 6, 12, and 18 hours postpartum)
Trial: 30630805
Drug: Mesalazine +
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalazine + Bifid Triple Viable Capsules
Trial: 26197940
Drug: Short-term oral
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term oral immunotherapy (OIT) with Cry j1-galactomannan conjugate
Trial: 28509487
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of perindopril and lozartan potassium
Trial: 28509487
Drug: Long-term monotherapy
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term monotherapy with perindopril
Trial: 21131668
Drug: 3 to
RxNorm normalized name: Melquin-3 Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 to 12 mg/d rivastigmine capsules
Trial: 21131668
Drug: Rivastigmine patch
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine patch groups
Trial: 18427220
Drug: Single-point injection
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-point injection of botulinum toxin A into one site
Trial: 18427220
Drug: Multiple-points injection
RxNorm normalized name: brilliant green
DrugBank: Brilliant green cation (DB11279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple-points injection of botulinum toxin A into two sites on both heads of the gastrocnemius
Trial: 18427220
Drug: Single-point injection
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-point injection of botulinum toxin A
Trial: 12791614
Drug: Original wheat
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original wheat germ containing 328 mg phytosterols
Trial: 30637889
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation (tDCS) treatment regimen (2 mA current, 30 min sessions, twice a week for up to 24 weeks)
Trial: 30637889
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation (tDCS) treatment
Trial: 21345487
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (10 days of omeprazole plus a single three-in-one capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline)
Trial: 21345487
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (7 days of omeprazole, amoxicillin, and clarithromycin)
Trial: 19321567
Drug: Leucine supplementation
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine supplementation (2.5 g with each main meal for 3 months)
Trial: 19321567
Drug: Placebo supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplementation (2.5 g with each main meal for 3 months)
Trial: 17348758
Drug: Group music
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group music therapy carried out once weekly for 2 years
Trial: 17348758
Drug: Nonmusic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonmusic therapy group
Trial: 15353506
Drug: Routine abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine abciximab administration
Trial: 15353506
Drug: Reperfusion modality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reperfusion modality (stents or glycoprotein IIb/IIIa inhibitors)
Trial: 31504982
Drug: General recommendations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General recommendations of good oral hygiene including teeth brushing, daily antiseptic mouthwash, and twice a year scaling.
Trial: 31504982
Drug: General recommendations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General recommendations of good oral hygiene.
Trial: 28891408
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two matched placebo tablets)
Trial: 23170931
Drug: Colesevelam 3.75 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam 3.75 g/day plus rosuvastatin 5 mg/day (RC, n=20)
Trial: 23170931
Drug: Rosuvastatin 10 mg
RxNorm normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 10 mg (R, n=20)
Trial: 21950641
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg (single oral dose)
Trial: 21950641
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg twice/day for 5 days followed by atorvastatin 20 mg (single oral dose) on day 4
Trial: 16966616
Drug: Fixed brimonidine-timolol
RxNorm normalized name: brimonidine / timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed brimonidine-timolol (0.2% brimonidine tartrate and 0.5% timolol maleate) twice daily
Trial: 16966616
Drug: 0.2% brimonidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% brimonidine tartrate 3 times daily
Trial: 1459516
Drug: Octylonium bromide
RxNorm normalized name: octylonium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octylonium bromide 40 mg tid for 4 weeks
Trial: 30289478
Drug: Isavuconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isavuconazole (200 mg IV TID for 2 days, then 200 mg IV OD)
Trial: 30289478
Drug: Caspofungin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin (70 mg IV OD on day 1, then 50 mg IV OD)
Trial: 16723306
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptives (COCs) with different estrogen/progestogen profiles: EE 20 microg/desogestrel 150 microg, EE 30 microg/desogestrel 150 microg, EE 30 microg/gestodene 75 microg
Trial: 3524923
Drug: Steroid and
RxNorm normalized name: Corticosteroid and/or corticosteroid derivative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid and chlorambucil for six months
Trial: 27101669
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy (SIT) and standardized treatment (glucocorticoid nasal spray)